Published in Eur J Neurol on February 01, 2006
Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm (Vienna) (2009) 1.12
Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm (Vienna) (2008) 1.05
Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat (2007) 1.02
Use of botulinum toxin in the neurology clinic. Nat Rev Neurol (2010) 0.95
Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm (Vienna) (2009) 0.94
Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol (2008) 0.92
Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics (2014) 0.88
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clin Pharmacol (2013) 0.87
Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging (2010) 0.86
X-linked dystonia parkinsonism: clinical phenotype, genetics and therapeutics. J Mov Disord (2010) 0.84
Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat (2012) 0.82
Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord (2014) 0.82
Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model. J Clin Aesthet Dermatol (2011) 0.81
AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm (Vienna) (2012) 0.79
Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A. J Med Chem (2013) 0.78
Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y) (2012) 0.78
Evidence based medicine on the use of botulinum toxin for headache disorders. J Neural Transm (Vienna) (2007) 0.77
Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. Head Face Med (2009) 0.75
Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis. Dermatol Res Pract (2013) 0.75
Conversion Ratio between Botox(®), Dysport(®), and Xeomin(®) in Clinical Practice. Toxins (Basel) (2016) 0.75
A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases. Toxins (Basel) (2015) 0.75
DNA replication: the rolling circle model. Cold Spring Harb Symp Quant Biol (1968) 8.37
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Adenovirus-2 DNA contains an inverted terminal repetition. Proc Natl Acad Sci U S A (1972) 4.57
A potential noninvasive neurobiological test for Alzheimer's disease. Science (1994) 4.29
Molecular mechanisms in genetic recombination. Annu Rev Biochem (1982) 3.03
Initiation and reinitiation of DNA synthesis during replication of bacteriophage T7. Proc Natl Acad Sci U S A (1972) 2.95
Bacteriophage T7 DNA replication: a linear replicating intermediate (gradient centrifugation-electron microscopy-E. coli-DNA partial denaturation). Proc Natl Acad Sci U S A (1972) 2.87
On the mechanism of genetic recombination: electron microscopic observation of recombination intermediates. Proc Natl Acad Sci U S A (1976) 2.19
The amplification of ribosomal RNA genes involves a rolling circle intermediate. Proc Natl Acad Sci U S A (1973) 2.07
Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology (2003) 1.89
dnaG (primase)-dependent origins of DNA replication. Nucleotide sequences of the negative strand initiation sites of bacteriophages St-1, phi K, and alpha 3. J Biol Chem (1979) 1.82
Transfer factor. Ann Intern Med (1974) 1.65
Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol (1997) 1.61
Site-specific initiation of a DNA fragment: nucleotide sequence of the bacteriophage G4 negative-strand initiation site. Proc Natl Acad Sci U S A (1978) 1.57
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther (1997) 1.55
The rolling circle for phiX DNA replication. II. Synthesis of single-stranded circles. Proc Natl Acad Sci U S A (1970) 1.48
In vitro system from Escherichia coli that catalyzes generalized genetic recombination. Proc Natl Acad Sci U S A (1978) 1.40
Regions of single-stranded DNA in the growing points of replicating bacteriophage T7 chromosomes. Proc Natl Acad Sci U S A (1972) 1.37
Effect of digital nerve stimuli on responses to electrical or magnetic stimulation of the human brain. J Physiol (1992) 1.35
On the mechanism of genetic recombination: the maturation of recombination intermediates. Proc Natl Acad Sci U S A (1977) 1.24
Analysis of the phiX DNA replication cycle by electron microscopy. Proc Natl Acad Sci U S A (1978) 1.19
The rolling circle for phi X DNA replication. 3. Synthesis of supercoiled duplex rings. Proc Natl Acad Sci U S A (1970) 1.17
The nucleolus and the rolling circle. Cold Spring Harb Symp Quant Biol (1974) 1.17
A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res (2009) 1.17
Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur J Neurol (2006) 1.15
Biochemical assay designed to detect formation of recombination intermediates in vitro. Proc Natl Acad Sci U S A (1979) 1.11
The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther (2001) 1.09
Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol (2000) 1.07
Transcranial electric and magnetic stimulation of the leg area of the human motor cortex: single motor unit and surface EMG responses in the tibialis anterior muscle. Electroencephalogr Clin Neurophysiol (1993) 1.07
Further observations on the facilitation of muscle responses to cortical stimulation by voluntary contraction. Electroencephalogr Clin Neurophysiol (1991) 1.04
A 'Southern Cross' method for the analysis of genome organization and the localization of transcription units. Gene (1986) 1.02
Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol (2001) 1.02
Transfer factor: a subcellular component that transmits information for specific immune responses. Proc Natl Acad Sci U S A (1974) 1.02
Nerve growth factor induces neuron-like differentiation of an insulin-secreting pancreatic beta cell line. Proc Natl Acad Sci U S A (1993) 1.01
Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn Schmiedebergs Arch Pharmacol (1980) 0.99
Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol (1981) 0.99
Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.98
On the chemical nature of transfer factor. Proc Natl Acad Sci U S A (1974) 0.98
Differential effects of tetanus toxin on inhibitory and excitatory synaptic transmission in mammalian spinal cord neurons in culture: a presynaptic locus of action for tetanus toxin. J Neurophysiol (1987) 0.96
Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology (2005) 0.96
Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol (1999) 0.96
Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology (2004) 0.94
Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol (2001) 0.92
Bacteriophage T7 DNA replication. An electron microscopic study of the growing point and the role of the T7 gene 4 protein in the formation of DNA fragments. J Biol Chem (1979) 0.92
The rolling circle . capsid complex as an intermediate in phi X DNA replication and viral assembly. J Biol Chem (1980) 0.91
Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture. Brain Res (1985) 0.91
GPi-DBS may induce a hypokinetic gait disorder with freezing of gait in patients with dystonia. Neurology (2011) 0.91
Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol (1995) 0.90
IgA protease from Neisseria gonorrhoeae inhibits exocytosis in bovine chromaffin cells like tetanus toxin. J Biol Chem (1995) 0.90
Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain (2001) 0.90
Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm (Vienna) (2002) 0.89
Quantitation of free and total amphotericin B in human biologic matrices by a liquid chromatography tandem mass spectrometric method. Ther Drug Monit (2001) 0.89
New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia. J Neurol Neurosurg Psychiatry (2007) 0.88
Higher prevalence of obsessive-compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm. Am J Psychiatry (1998) 0.88
Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure. Toxicon (1986) 0.88
Differential effects of various secretagogues on quantal transmitter release from mouse motor nerve terminals treated with botulinum A and tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol (1987) 0.88
Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord (2000) 0.88
On muscle spindles, dystonia and botulinum toxin. Eur J Neurol (2010) 0.87
Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc (1998) 0.87
Abnormal interaction between vestibular and voluntary head control in patients with spasmodic torticollis. Brain (2001) 0.87
Tetanus toxin in dissociated spinal cord cultures: long-term characterization of form and action. J Neurochem (1986) 0.87
Botulinum toxin therapy of writer's cramp. Eur J Neurol (2006) 0.87
Site-specific initiation of a DNA fragment. Proc Natl Acad Sci U S A (1978) 0.87
Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation. J Heart Lung Transplant (2001) 0.87
Single-stranded phage replication: positive- and negative-strand DNA synthesis. Cold Spring Harb Symp Quant Biol (1979) 0.86
Botulinum neurotoxin - from laboratory to bedside. Neurotox Res (2006) 0.86
Botulism type B presenting as pure autonomic dysfunction. Clin Auton Res (2003) 0.85
Suppression of 3H-acetylcholine release from primary nerve cell cultures by tetanus and botulinum-A toxin. Naunyn Schmiedebergs Arch Pharmacol (1978) 0.85
Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry (1993) 0.84
Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. Eur Arch Otorhinolaryngol (1997) 0.83
Machado-Joseph disease presenting as severe generalised dystonia in a German patient. J Neurol (1999) 0.83
[Pathophysiological data and their consequences on diagnosis and therapy of degenerative joint diseases]. Med Monatsschr (1975) 0.83
The potential of BACE inhibitors for Alzheimer's therapy. Nat Biotechnol (2000) 0.83
Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res (2006) 0.83
[Anti-inflammatory action of a hyaluronic acid-chondroitin sulfate preparation in an in vitro bladder model]. Aktuelle Urol (2009) 0.82
DNA recombination: in vivo and in vitro studies. Cold Spring Harb Symp Quant Biol (1979) 0.82
Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells. Toxicon (1989) 0.82
Tetanus toxin: inhibitory action in chromaffin cells is initiated by specified types of gangliosides and promoted in low ionic strength solution. Neurosci Lett (1989) 0.82
The recent excitement in the DNA growing point problem. Annu Rev Microbiol (1975) 0.82
Overactive bladder in Parkinson's disease: alteration of brainstem raphe detected by transcranial sonography. Eur J Neurol (2006) 0.81
Tetanus and botulinum A toxins inhibit stimulated F-actin rearrangement in chromaffin cells. Neuroreport (1991) 0.81
Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol (1980) 0.81
Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy. Neuropediatrics (2000) 0.81
Sonographic detection of basal ganglia abnormalities in spasmodic dysphonia. Eur J Neurol (2013) 0.81
Another case of focal segmental glomerulosclerosis in an acutely uraemic patient following interferon therapy. Nephrol Dial Transplant (1999) 0.81
Bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design. J Clin Pharmacol (1999) 0.81
Inhibition of synaptosomal choline uptake by tetanus and botulinum A toxin. Partial dissociation of fixation and effect of tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol (1981) 0.80
Distinct targets for tetanus and botulinum A neurotoxins within the signal transducing pathway in chromaffin cells. Naunyn Schmiedebergs Arch Pharmacol (1991) 0.80
DNA synaptase: an enzyme that fuses DNA molecules at a region of homology. Proc Natl Acad Sci U S A (1980) 0.80
Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry (2002) 0.80
Rapid rate transcranial magnetic stimulation--a safety study. Electroencephalogr Clin Neurophysiol (1997) 0.80
Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiatry (1998) 0.79
Tetanus antitoxin binds to intracellular tetanus toxin in permeabilized chromaffin cells without restoring Ca2(+)-induced exocytosis. Toxicon (1990) 0.79
Results of a BoNT/A antibody study in children and adolescents after onabotulinumtoxin A (Botox®) detrusor injection. Urol Int (2011) 0.79
Transfer factor: warning on uncertainty of results. Ann Intern Med (1975) 0.79
Uptake of antitetanus F(ab')2 fragments into eukaryotic cells. J Physiol (Paris) (1990) 0.78
Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol (2000) 0.78
Processing of tetanus and botulinum A neurotoxins in isolated chromaffin cells. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.78
[Gout, pseudo-gout or hyperlipoproteinemia? (author's transl)]. Z Orthop Ihre Grenzgeb (1976) 0.78
Dyskinesias possibly induced by norpseudoephedrine. J Neurol (1994) 0.78